Abstract: A device for concentrating and preserving samples for subsequent analysis, wherein the samples include but are not limited to, biological samples, environmental samples, industrial samples, and the like. The present disclosure further includes a method for utilizing the device for containment, concentration, and preservation of the sample until analysis can take place. The disclosed device is simple to operate and can function without auxiliary equipment and/or sources of power making it particularly suitable for use in locations distanced and isolated from analytical facilities.

Abstract: It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

Abstract: A method and formulation for temperature stabilization of proteins, such as antibodies, enzymes such as Taq poly-merase, restriction enzymes, and other diagnostic or therapeutic enzymes using a combination of first and second stabilizers.

Abstract: A non-respirable aerosol, particularly a non-respirable aerosol comprising a biologically-effective amount of a biologically-active agent dissolved, emulsified, or suspended in a highly-aqueous liquid carrier vehicle. The highly-aqueous liquid carrier vehicle comprises about 60 wt % to about 100 wt % water, about 0 wt % to about 40 wt % of a co-solvent, about 0.05 wt % to about 10 wt % of an acceptable surfactant, and about 0 wt % to about 10 wt % of an excipient. The non-respirable aerosol is substantially monodisperse when dispensed from a sprayhead assembly comprising a preferably linear array of a plurality of nozzles and at least one counter electrode adapted to substantially equalize the charge fields of the plurality of nozzles.